- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05057897
A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults (VICTORIA)
A Phase IV Open-Label, Non-Randomized, Multi-Cohort, Multicenter Study in Previously Unvaccinated Immunocompromised Adults to Determine the Immunogenicity and Safety of AZD1222 Vaccine for the Prevention of COVID-19
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult, ≥ 18 years at the time of signing the informed consent.
- Cohort specific inclusion criteria:
Solid organ transplant
- Participants with heart, lung, kidney, or liver transplant, and are stable on immunosuppressants (defined as no change in dose in the previous 4 weeks).
Hematopoietic stem cell transplant
- Participants with autologous (up to 6 months after transplantation) or allogeneic stem cell transplant who are immunosuppressed, with no evidence of active graft-versushost disease, at least one month after the procedure.
Cancer patients on chemotherapy
- Participants with solid tumors (except breast cancer), histologically diagnosed, who were undergoing intravenous cytotoxic chemotherapy within the last 6 months, who received at least 1 cycle prior to cytotoxic chemotherapy, and have a life expectancy of longer than 3 months.
Chronic inflammatory conditions
- Participants with chronic inflammatory conditions, including those on immunosuppressant medications, can be recruited. The following conditions are specifically excluded: multiple sclerosis and peripheral demyelinating disease.
Primary immune deficiency
- Examples include combined granulomatous disorder, SCID, common variable immunodeficiency.
Immunocompetent:
- No confirmed or suspected immunosuppressive or immunodeficient state.
- No use of immunosuppressant medication within the past 1 month (≥ 20 mg per day of prednisone or its equivalent, given daily or on alternate days for ≥ 15 days within 30 days prior to administration of AZD1222). The following exceptions are permitted: topical/inhaled steroids or short-term oral steroids (course lasting ≤ 14 days).
- No receipt of immunoglobulins and/or any blood products within 3 months prior to administration of AZD1222 or expected receipt during the period of study follow up.
- No severe and/or uncontrolled cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder, and neurological illness, as judged by the Investigator.
Exclusion Criteria:
- History of allergic disease or reactions likely to be exacerbated by any component of AZD1222.
- Active infection with SARS-CoV-2 as confirmed locally by nucleic acid amplification test (e.g. RT-PCR).
- Known current or past laboratory-confirmed SARS-CoV-2 infection.
- Significant infection or other acute illness, including fever (temperature > 37.8°C) on the day prior to or day of first dosing.
- Thrombocytopenia with platelet count ≤ 75,000 x 109/microliter based on complete blood count test at screening visit.
- HIV-positive participants based on a positive ELISA test performed at screening visit.
- History of cerebral venous sinus thrombosis (CVST).
- Receipt of any vaccine (licensed or investigational) within 30 days prior to and after administration of AZD1222.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Cohort 1 - immunocompromised participants with solid organ transplant
Previously unvaccinated immunocompromised participants with solid organ transplant will receive a primary vaccination series with 3 IM doses of AZD1222 separated by 4 weeks and will be followed to the end of the study.
The first dose will be administered on Day 1, the second dose will be administered 28 days after dose 1, and the third dose will be administered 28 days after dose 2.
|
10 mM histidine, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6
|
Other: Cohort 2 - immunocompromised participants with hematopoietic stem cell transplant
Previously unvaccinated immunocompromised participants with hematopoietic stem cell transplant will receive a primary vaccination series with 3 IM doses of AZD1222 separated by 4 weeks and will be followed to the end of the study.
The first dose will be administered on Day 1, the second dose will be administered 28 days after dose 1, and the third dose will be administered 28 days after dose 2.
|
10 mM histidine, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6
|
Other: Cohort 3 - immunocompromised participants with solid organ cancer receiving cytotoxic chemotherapy
Previously unvaccinated immunocompromised participants with solid organ cancer receiving cytotoxic chemotherapy will receive a primary vaccination series with 3 IM doses of AZD1222 separated by 4 weeks and will be followed to the end of the study.
The first dose will be administered on Day 1, the second dose will be administered 28 days after dose 1, and the third dose will be administered 28 days after dose 2.
|
10 mM histidine, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6
|
Other: Cohort 4 - immunocompromised participants with chronic inflammatory disorders
Previously unvaccinated immunocompromised participants with chronic inflammatory disorders will receive a primary vaccination series with 3 IM doses of AZD1222 separated by 4 weeks and will be followed to the end of the study.
The first dose will be administered on Day 1, the second dose will be administered 28 days after dose 1, and the third dose will be administered 28 days after dose 2.
|
10 mM histidine, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6
|
Other: Cohort 5 - immunocompromised participants with primary immunodeficiency
Previously unvaccinated immunocompromised participants with primary immunodeficiency will receive a primary vaccination series with 3 IM doses of AZD1222 separated by 4 weeks and will be followed to the end of the study.
The first dose will be administered on Day 1, the second dose will be administered 28 days after dose 1, and the third dose will be administered 28 days after dose 2.
|
10 mM histidine, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6
|
Other: Cohort 6 - immunocompetent participants
Previously unvaccinated immunocompetent participants will receive a primary vaccination series with 2 IM doses of AZD1222 separated by 4 weeks, followed by a booster dose of AZD1222 administered 6 months after the first dose.
The first dose will be administered on Day 1, the second dose will be administered 28 days after dose 1. Participants will receive a third dose booster 6 months after dose 1 and will continue to be followed to the end of the study.
|
10 mM histidine, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SARS-CoV-2 specific titres in SARS-CoV-2 naïve immunocompromised adults and immunocompetent adults ≥ 18 years
Time Frame: 28 days after dosing
|
Characterization of immunogenicity of a 2-dose primary vaccination with AZD1222 with a 4-week dosing interval
|
28 days after dosing
|
Seroresponse of SARS-CoV-2 specific titres (≥ 4-fold rise in titres from baseline) in SARS-CoV-2 naïve immunocompromised adults and immunocompetent adults ≥ 18 years
Time Frame: 28 days after dosing
|
Characterization of immunogenicity of a 2-dose primary vaccination with AZD1222 with a 4-week dosing interval
|
28 days after dosing
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ratio of SARS-CoV-2 specific GMT titres in adults ≥ 18 years with a 4-week dosing interval between SARS-CoV-2 naïve participants with any immunocompromised condition compared to immunocompetent participants
Time Frame: 28 days after Dose 2
|
Description of the immunogenicity of a 2-dose primary vaccination with AZD1222
|
28 days after Dose 2
|
Difference in seroresponse rates of SARS-CoV-2 specific titres in adults ≥ 18 years with a 4-week dosing interval between SARS-CoV-2 naïve participants with any immunocompromised condition compared to immunocompetent participants
Time Frame: 28 days after Dose 2
|
Description of the immunogenicity of a 2-dose primary vaccination with AZD1222, with a difference of ≥ 4-fold rise in titres from baseline
|
28 days after Dose 2
|
Incidence of local and systemic solicited AEs after dosing in SARS-CoV-2 naïve immunocompromised adults ≥ 18 years
Time Frame: For 7 days after each dose of AZD1222
|
Characterization of the reactogenicity and safety of a 3-dose primary vaccination series with AZD1222 with a 4-week dosing interval
|
For 7 days after each dose of AZD1222
|
Incidence of unsolicited AEs after dosing in SARS-CoV-2 naïve immunocompromised adults ≥ 18 years
Time Frame: For 28 days post dose after each vaccination (i.e., until Day 29 following the first vaccination and Day 57 following the second vaccination) and Day 85 following the 3rd vaccination
|
Characterization of the reactogenicity and safety of a 3-dose primary vaccination series with AZD1222 with a 4-week dosing interval
|
For 28 days post dose after each vaccination (i.e., until Day 29 following the first vaccination and Day 57 following the second vaccination) and Day 85 following the 3rd vaccination
|
Incidence of SAEs, MAAEs and AESIs in SARS-CoV-2 naïve immunocompromised adults ≥ 18 years
Time Frame: From Day 1 post treatment to the last study visit
|
Characterization of the reactogenicity and safety of a 3-dose primary vaccination series with AZD1222 with a 4-week dosing interval
|
From Day 1 post treatment to the last study visit
|
Absolute and change from baseline for safety laboratory measures in SARS-CoV-2 naïve immunocompromised adults ≥ 18 years
Time Frame: Through 28 days after 3rd dose
|
Characterization of the reactogenicity and safety of a 3-dose primary vaccination series with AZD1222 with a 4-week dosing interval
|
Through 28 days after 3rd dose
|
Ratio of SARS-CoV-2 specific GMT titres in adults ≥ 18 years with a 4-week dosing interval between SARS-CoV-2 naïve participants in the comparator cohort as compared with immunocompetent participants
Time Frame: 28 days after Dose 2
|
Description of the immunogenicity of a 2-dose primary vaccination with AZD1222 Comparator cohorts: solid organ transplant/hematopoietic stem cell transplant/solid organ cancer patients receiving cytotoxic chemotherapy/chronic inflammatory disorders/primary immunodeficiency |
28 days after Dose 2
|
Difference in seroresponse rates of SARS-CoV-2 specific titres in adults ≥ 18 years with a 4-week dosing interval between SARS-CoV-2 naïve participants in the comparator cohort as compared with immunocompetent participants
Time Frame: 28 days after Dose 2
|
Description of the immunogenicity of a 2-dose primary vaccination with AZD1222, with a difference of ≥ 4-fold rise in titres from baseline Comparator cohorts: solid organ transplant/hematopoietic stem cell transplant/solid organ cancer patients receiving cytotoxic chemotherapy/chronic inflammatory disorders/primary immunodeficiency |
28 days after Dose 2
|
SARS-CoV-2 specific titres in immunocompromised adults ≥ 18 years
Time Frame: 28 days after Dose 3
|
Characterization of immunogenicity after a 3rd-dose in a 3 dose primary vaccination series with AZD1222
|
28 days after Dose 3
|
Seroresponse of SARS-CoV-2 specific titres (≥ 4-fold rise in titres from baseline) in immunocompromised adults ≥ 18 years
Time Frame: 28 days after Dose 3
|
Characterization of immunogenicity after a 3rd-dose in a 3 dose primary vaccination series with AZD1222
|
28 days after Dose 3
|
Ratio of SARS-CoV-2 specific GMT titres in adults ≥ 18 years between SARS-CoV-2 naïve immunocompromised participants compared to immunocompetent participants after a 2-dose primary vaccination
Time Frame: 28 days after Dose 3 (28 Days after Dose 2 for reference cohort)
|
Description of immunogenicity after the 3rd dose in a 3-dose primary vaccination with AZD1222 Comparator cohort: Each of 5 immunocompromised cohorts and pooled immunocompromised cohorts Reference cohort: Immunocompetent |
28 days after Dose 3 (28 Days after Dose 2 for reference cohort)
|
Difference in seroresponse rate of SARS-CoV-2 specific GMT titres in adults ≥ 18 years between SARS-CoV-2 naïve immunocompromised participants compared to immunocompetent participants after a 2-dose primary vaccination
Time Frame: 28 days after Dose 3 (28 Days after Dose 2 for reference cohort)
|
Description of immunogenicity after the 3rd dose in a 3-dose primary vaccination with AZD1222 with a difference of ≥ 4-fold rise in titres from baseline Comparator cohort: Each of 5 immunocompromised cohorts and pooled immunocompromised cohorts Reference cohort: Immunocompetent |
28 days after Dose 3 (28 Days after Dose 2 for reference cohort)
|
Ratio of SARS-CoV-2 specific GMT titres in adults ≥ 18 years between SARS-CoV-2 naïve immunocompromised and immunocompetent participants
Time Frame: 28 Days after Dose 2 and 28 Days after Dose 3
|
Description of immunogenicity of the AZD1222 vaccination between 28 days post second dose compared to 28 days post third dose
|
28 Days after Dose 2 and 28 Days after Dose 3
|
Difference in seroresponse rates of SARS-CoV-2 specific titres in adults ≥ 18 years between SARS-CoV-2 naïve immunocompromised and immunocompetent participants
Time Frame: 28 Days after Dose 2 and 28 Days after Dose 3
|
Description of immunogenicity of the AZD1222 vaccination between 28 days post second dose compared to 28 days post third dose with a difference of ≥ 4 fold increase in titres from 28 days post dose 2 to 28 days post dose 3
|
28 Days after Dose 2 and 28 Days after Dose 3
|
SARS-CoV-2 specific titres in immunocompetent adults ≥ 18 years
Time Frame: 28 days after Dose 3
|
Characterization of the immunogenicity after a third-dose booster vaccination of AZD1222, administered 6 months after dose 1 of a 2-dose primary vaccination with AZD1222
|
28 days after Dose 3
|
Seroresponse of SARS-CoV-2 specific titres (≥ 4-fold rise in titres from baseline) in immunocompetent adults ≥ 18 years
Time Frame: 28 days after Dose 3
|
Characterization of the immunogenicity after a third-dose booster vaccination of AZD1222, administered 6 months after dose 1 of a 2-dose primary vaccination with AZD1222
|
28 days after Dose 3
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- D8111C00010
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19, SARS-CoV-2
-
AstraZenecaActive, not recruitingCOVID-19, SARS-CoV-2Japan
-
University of Wisconsin, MadisonNational Institutes of Health (NIH)Completed
-
Syneos HealthUS Specialty Formulations, LLCCompletedSARS-CoV-2 (COVID-19)New Zealand
-
Mayo ClinicCompletedCOVID-19 | SARS-CoV 2United States
-
St. Olavs HospitalThe Research Council of Norway; Helse Nord-Trøndelag HF; Alesund Hospital; Namsos... and other collaboratorsCompletedSARS-CoV-2 Acute Respiratory Disease | SARS-CoV-2 Sepsis | SARS CoV 2 InfectionNorway
-
Boston UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Burnet Institute and other collaboratorsRecruitingSARS CoV 2 Infection | SARS CoV 2 VaccinationUnited States, Malawi
-
University of MelbourneThe George Institute; The University of Queensland; The Peter Doherty Institute... and other collaboratorsRecruitingSARS-CoV-2 Infection (COVID-19)Australia
-
Medical University InnsbruckRecruitingSARS-CoV-2 | Post-acute COVID-19 SyndromeAustria
-
Stanford UniversityPfizerCompletedLong COVID | Post-acute Sequelae of SARS-CoV-2 InfectionUnited States
-
The Board of MedicineApollo Neuroscience, Inc.RecruitingPost-acute Sequelae of SARS-COV-2 InfectionUnited States
Clinical Trials on AZD1222
-
Imperial College LondonAstraZeneca; University of OxfordActive, not recruitingCovid19 | SARS-CoV-2 InfectionUnited Kingdom
-
AstraZenecaRTI Health SolutionsCompletedCOVID-19, Vaccine Adverse Events of Special InterestNetherlands, Spain, United Kingdom
-
AstraZenecaCovance; Iqvia Pty LtdWithdrawn
-
Federal University of Espirito SantoInstituto René Rachou/Fiocruz; Escola Nacional de Saúde Pública Sérgio Arouca... and other collaboratorsRecruiting
-
Chang Gung Memorial HospitalRecruitingHealthy | Covid-19 | Vaccine | Immunogenicity | ReactogenicityTaiwan
-
Albert B. Sabin Vaccine InstituteStanford University; Aga Khan University; Oswaldo Cruz FoundationCompleted
-
Federal University of Espirito SantoInstituto René Rachou/FiocruzRecruiting
-
Humanity & Health Medical Group LimitedCompleted
-
Shabir MadhiAstraZenecaCompletedCOVID-19 | Pneumonia, ViralSwaziland
-
AstraZenecaIqvia Pty LtdCompleted